A Florida company with a technology for reformulating oily drugs so they can be delivered intravenously is moving its headquarters and research lab to Wisconsin. An investment by Kegonsa Partners and a grant from the state Department of Commerce were instrumental. Click here to read a Milwaukee Journal-Sentinel story.